Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Shaman Pharmaceuticals has been moving on big, relative, -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (812)	12/7/2000 11:57:50 AM
From: Daniel Shaffer	Respond to of 838

Crisis and Opportunity Apparently the GNC store stocking of NSF was delayed when GNC was acquired by NUMICO of Netherlands. Shaman has a great window of opportunity right now to cash in on the withdrawal of prescription IBS drugs from the marketplace. If they just focus their attention and available human resources on low-cost guerilla marketing to IBS patients and their doctors, we may see a turnaround. The weight loss formulation they are testing at Stanford could be the biggest nutriceutical to ever hit the market if it pans out. Do you have any indication of success to date for the Syndrome X campaign? How credible is the good doctor who wrote the book? I certainly hope they don't pull another dilution financing. If they do, my original stock will be worth nanocents per share.